BioSpace News Archive

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company’s interim report for the period January-June 2023, has been published.

Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism.

Asieris Pharmaceuticals announced that the National Medical Products Administration has approved the Investigational Drug application for its oral drug APL-1401 for the treatment of moderately-to-severely active ulcerative colitis.The IND application had previously been approved by the U.S. Food and Drug Administration.

BioInvent International “In the quarter, we had impressive early signals of efficacy in the Phase 1/2 trial of our lead drug candidate, the novel anti-FcgRIIB antibody BI-1206, in combination with rituximab in non-Hodgkin’s lymphoma.

Emergent BioSolutions Inc. announced NARCAN® Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online beginning in September.

Outlook Therapeutics, Inc. announced the U.S. Food and Drug Administration has issued a CRL to the Company’s BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.

SOPHiA GENETICS announced that CHU Bordeaux, a full-service hospital servicing the population of Bordeaux and the surrounding area, has completed implementation of the SOPHiA DDM™ Platform into its organization.

Oculis Holding AG announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences:

As announced in July, we are significantly restructuring Immunovia to focus on our novel next-generation test for detection of pancreatic cancer.

Johnson & Johnson announced updates to its financials and 2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech.